Mesoblast
Market Cap
AU$951.7m
Last Updated
2019/10/17 10:31 UTC
Data Sources
Company Financials +
Executive Summary
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines.
Snowflake
Fundamentals
High growth potential with imperfect balance sheet.
Similar Companies
Share Price & News
How has Mesoblast's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-2.9%
MSB
5.1%
AU Biotechs
2.5%
AU Market
1 Year Return
-10.4%
MSB
32.2%
AU Biotechs
11.1%
AU Market
Return vs Industry: MSB underperformed the Australian Biotechs industry which returned 32.2% over the past year.
Return vs Market: MSB underperformed the Australian Market which returned 11.1% over the past year.
Shareholder returns
| MSB | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.9% | 5.1% | 2.5% |
| 30 Day | -16.6% | 9.9% | 0.7% |
| 90 Day | 24.0% | 13.5% | 1.4% |
| 1 Year | -10.4%-10.4% | 33.8%32.2% | 17.5%11.1% |
| 3 Year | 62.5%60.9% | 145.8%136.9% | 37.8%19.4% |
| 5 Year | -51.2%-51.7% | 238.1%216.2% | 51.7%17.6% |
Price Volatility Vs. Market
How volatile is Mesoblast's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Mesoblast (ASX:MSB) Is Carrying A Fair Bit Of Debt3 months ago | Simply Wall St
When Will Mesoblast Limited (ASX:MSB) Breakeven?3 months ago | Simply Wall St
Does Market Volatility Impact Mesoblast Limited's (ASX:MSB) Share Price?Valuation
Is Mesoblast undervalued compared to its fair value and its price relative to the market?
1.26x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: Insufficient data to calculate MSB's fair value to establish if it is undervalued.
Significantly Undervalued: Insufficient data to calculate MSB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MSB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MSB is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate MSB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MSB is good value based on its PB Ratio (1.3x) compared to the AU Biotechs industry average (3.1x).
Next Steps
Future Growth
How is Mesoblast forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
54.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MSB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: MSB is forecast to become profitable over the next 3 year, which is considered above average market growth.
High Growth Earnings: MSB's loss is forecast to worsen by 0% next year.
Revenue vs Market: MSB's revenue (47.4% per year) is forecast to grow faster than the Australian market (3.6% per year).
High Growth Revenue: MSB's revenue (47.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: MSB is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Mesoblast performed over the past 5 years?
6.5%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: MSB is unprofitable, but has reduced losses over the past 5 years at a rate of 6.5% per year.
Accelerating Growth: Unable to compare MSB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MSB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.2%).
Return on Equity
High ROE: MSB has a negative Return on Equity (-18.67%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: MSB is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: MSB is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Mesoblast's financial position?
Financial Position Analysis
Short Term Liabilities: MSB's short term assets ($62.5M) exceeds its short term liabilities ($44.3M)
Long Term Liabilities: MSB's short term assets (62.5M) do not cover its long term liabilities (126.7M)
Debt to Equity History and Analysis
Debt Level: MSB's debt to equity ratio (16.9%) is considered satisfactory
Reducing Debt: Insufficient data to determine if MSB's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: MSB has a low level of unsold assets or inventory.
Debt Coverage by Assets: MSB's debt is not covered by short term assets (assets are 0.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MSB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MSB has less than a year of cash runway if free cash flow continues to grow at historical rates of 14.5% each year.
Next Steps
Dividend
What is Mesoblast's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate MSB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MSB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if MSB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MSB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MSB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
What is the CEO of Mesoblast's salary, the management and board of directors tenure and is there insider trading?
8.8yrs
Average management tenure
CEO
Silviu Itescu (62yo)
8.8yrs
Tenure
US$1,927,278
Compensation
Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesobla ...
CEO Compensation Analysis
Compensation vs. Market: Silviu's total compensation ($USD1.30M) is about average for companies of similar size in the Australian market ($USD980.46K).
Compensation vs Earnings: Silviu's compensation has been consistent with company performance over the past year.
Management Age and Tenure
8.8yrs
Average Tenure
60yo
Average Age
Experienced Management: MSB's management team is seasoned and experienced (8.8 years average tenure).
Board Age and Tenure
6.5yrs
Average Tenure
66.5yo
Average Age
Experienced Board: MSB's board of directors are considered experienced (6.5 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 5,000,000 |
| Max Price | US$2.00 |
| Entity | Company |
| Shares | 3,681,270 |
| Max Price | US$1.53 |
| Entity | Company |
| Shares | 8,714,117 |
| Max Price | US$1.19 |
| Entity | Company |
| Shares | 2,721,380 |
| Max Price | US$1.22 |
Ownership Breakdown
Management Team
Jon Symonds (60yo)
Head of Corporate Finance & Strategy
- Tenure: 0yrs
Silviu Itescu (62yo)
Founder
- Tenure: 8.8yrs
- Compensation: US$1.93m
Julie Meldrum
Global Head of Corporate Communications
- Tenure: 0yrs
Donna Skerrett (62yo)
- Tenure: 8.8yrs
Michael Schuster (42yo)
Head of Pharma Partnering
- Tenure: 0yrs
Roger Brown
Head of Spinal Orthopedic Disorders
- Tenure: 4yrs
Paul Simmons (60yo)
Head of Research & New Product Development
- Tenure: 8.8yrs
John McMannis (63yo)
Head of Manufacturing
- Tenure: 8.8yrs
Peter Howard (51yo)
General Counsel & Corporate Executive
- Tenure: 8.3yrs
Josh Muntner (50yo)
Chief Financial Officer
- Tenure: 1.4yrs
- Compensation: US$892.41k
Board Members
Eric Rose (68yo)
Non Executive Director
- Tenure: 6.5yrs
- Compensation: US$150.00k
Joe Swedish (67yo)
Non-Executive Chairman
- Tenure: 0.5yrs
- Compensation: US$324.12k
Bill Burns (72yo)
Non-Executive Vice Chairman
- Tenure: 3.8yrs
- Compensation: US$201.26k
Donal O’Dwyer (66yo)
Non-Executive Director
- Tenure: 15.1yrs
- Compensation: US$180.69k
Silviu Itescu (62yo)
Founder
- Tenure: 8.8yrs
- Compensation: US$1.93m
Michael Spooner (62yo)
Non-Executive Director
- Tenure: 15.1yrs
- Compensation: US$180.69k
Henry Krum
Member of Scientific Advisory Board
- Tenure: 0yrs
Joseph Lane
Member of Scientific Advisory Board
- Tenure: 0yrs
Bob Graham
Member of Scientific Advisory Board
- Tenure: 0yrs
Richard Gilbert
Member of Scientific Advisory Board
- Tenure: 0yrs
Company Information
Mesoblast Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Mesoblast Limited
- Ticker: MSB
- Exchange: ASX
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$951.725m
- Shares outstanding: 533.18m
- Website: https://www.mesoblast.com
Number of Employees
Location
- Mesoblast Limited
- 55 Collins Street
- Level 38
- Melbourne
- Victoria
- 3000
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| LWB | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Dec 2004 |
| MSB | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Dec 2004 |
| MEOB.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Dec 2004 |
| MSB | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Dec 2004 |
| MESO | NasdaqGS (Nasdaq Global Select) | SPON ADR EACH REP 5 SHS | US | USD | Dec 2005 | |
| LWBA | DB (Deutsche Boerse AG) | SPON ADR EACH REP 5 SHS | DE | EUR | Dec 2005 |
Biography
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, h ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/17 10:31 |
| End of Day Share Price | 2019/10/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.